Perrigo’s court battle over €1.64bn tax bill begins

The pharma giant has challenged Revenue’s claim that the sale of a multiple sclerosis drug should have been subject to capital gains tax

3rd June, 2020
Perrigo’s court battle over €1.64bn tax bill begins
Tysabri, a multiple sclerosis drug, is at the centre of a dispute over the amount of tax paid by Elan on its sale. Perrigo bought Elan eight months after Elan had sold the drug’s intellectual property. Picture: Getty

Drug giant Perrigo’s high-profile challenge to Revenue‘s €1.64 billion tax bill is due to begin before the Commercial Court today.

Perrigo was issued the bill by the Revenue Commissioners in 2018. The sum involved is the largest to come from Revenue’s investigations and the second largest in the history of the state after the €13 billion Apple ruling by the European Commission.

The pharmaceutical company claims the government and Revenue...

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Green Party TD lodges appeal against high court Ceta ruling

Agreement paves way for potential deal between Ronan Group and Colony Capital

The clash of the Web Summit founders: the story behind the legal battle and what it means

Nephin Whiskey founder accused of diverting business to rival company